About this trial
This study compares the effectiveness of peloid therapy and paraffin treatment in carpal tunnel syndrome. Patients who have already received 2 weeks of peloid therapy or 15 sessions of paraffin treatment will be assessed. Pain and symptom severity are assessed using the Visual Analog Scale (VAS) and Boston Carpal Tunnel Syndrome Questionnaire (BCTQ). Electrophysiological examinations will also be conducted at the same time points: baseline, 4 weeks post-treatment, and a 12-week follow-up.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged between 18 and 65 years old.
Patients diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological evaluations.
Patients experiencing symptoms for a minimum of 3 months.
Disqualifiers
Patients diagnosed with neuropathic conditions such as polyneuropathy, brachial plexopathy, or thoracic outlet syndrome.
Patients with a history of previous injections or surgery for carpal tunnel syndrome.
Trial population
Patients with mild and moderate carpal tunnel syndrome
Trial design
Case-control
Other
Treatments tested in this trial
No intervention
Other interventionNo intervention.
Treatment groups
Trial outcomes
Primary outcomes
Boston Carpal Tunnel Syndrome Questionnaire
The Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) consists of two parts: the Symptom Severity Scale (SSS) and the Functional Status Scale (FSS). Both parts are scored on a 5-point Likert scale, with higher scores indicating worse symptoms or functional impairment.The highest possible total score for the Symptom Severity Scale is 55, which reflects the most severe symptoms.The highest possible total score for the Functional Status Scale is 40, indicating the greatest functional impairment.The minimum total score is 19 (indicating minimal or no symptoms and functional limitations). The maximum total score is 95 (indicating the most severe symptoms and functional limitations). As the total score increases, the severity of symptoms and functional limitations worsens, meaning higher scores reflect worse outcomes.
Secondary outcomes
Visual Analogue Scale
The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. The Visual Analog Scale (VAS) is a tool used to measure pain intensity. It is typically represented as a 10 cm or 100 mm line, where the patient marks their pain level. The minimum score is 0, which indicates no pain. The maximum score is 100, indicating the worst possible pain. As the score increases, the severity of pain worsens. In this scale, higher scores reflect more intense pain levels. The Visual Analog Scale (VAS) ranges from 0 to 100 where higher scores reflect greater pain intensity.
Median nerve distal motor latency
It is a finding from electrophysiological evaluation
Median nerve distal sensory latency
It is a finding from electrophysiological evaluation
Sensory nerve conduction velocity
It is a finding from electrophysiological evaluation
Sponsors and contacts
Click on the lead sponsor to view all of their trials.